To date, PD-L1 expression, tumor mutation burden (TMB), and microsatellite instability (MSI) have been used to predict the response to ICIs [7–9], but these do not necessarily preclude or not always correlate with clinical response [10, 11]. Here, CD274 is linked to neoplasm.